Gazyva FDA Approval History
FDA Approved: Yes (First approved November 1, 2013)
Brand name: Gazyva
Generic name: obinutuzumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Chronic Lymphocytic Leukemia, Follicular Lymphoma
Gazyva (obinutuzumab) is a CD20-directed cytolytic antibody indicated for the combination treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.
Development Timeline for Gazyva
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.